The chemokine receptor CCR5, a member of the seventransmembrane G-protein coupled family of receptors, 1) has been identified as a primary co-receptor with CD4 by which macrophage tropic human immunodeficiency virus type-1 (HIV-1) strains infect their host cells.
The chemokine receptor CCR5, a member of the seventransmembrane G-protein coupled family of receptors, 1) has been identified as a primary co-receptor with CD4 by which macrophage tropic human immunodeficiency virus type-1 (HIV-1) strains infect their host cells. 2) Since the discovery of CCR5 as a co-receptor with CD4 for HIV-1 cell entry, there has been interest in discovering small molecule CCR5 antagonists [3] [4] [5] [6] as well as CXCR4 antagonists 7) and HIV-1 protease inhibitors 8) as potential agents for the treatment of HIV-1 infection.
The entry of HIV-1 to cells involves the binding of the trimeric viral envelope glycoprotein gp120/gp41 to cell surface receptor CD4 and chemokine co-receptor CXCR4 or CCR5, which triggers conformational changes in the envelope proteins. Gp120 then dissociates from gp41, allowing for the fusion peptides to be inserted into the target membrane and the pre-hairpin configuration of the ectodomain to form. [9] [10] [11] Regulation of CCR5 number on cells is important in determining the infection rate by HIV-1. Therefore, CCR5 is a highly valued target for the treatment of HIV-1 infection.
It was demonstrated that the Gly-Gly-Gly sequence of the peptide moiety in lipopeptides could be replaced with a nonpeptide spacer. 12) We designed compounds with non-peptide spacers such as a benzene ring in place of the Ala-Ala-Ala sequence of the peptide moiety of CCR5. As part of a program aimed at the development of new HIV-1 inhibitors, [13] [14] [15] [16] [17] [18] we would like to report the design and synthesis of CCR5 peptide mimics derived from the first extracellular loop of CCR5 bearing non-peptide spacers in place of AlaAla-Ala sequence in the peptide moiety for prevention of HIV-1 infection based on a strategy of binding to gp120.
Results and Discussion
In the amino acid sequence of the N-terminal domain of CCR5, we chose the region of Tyr 89 -Gly 97 including alanine tripeptide. The peptide of natural type peptide 1 and its mimicking peptides 2a-c consisting of unnatural-type amino acids derived from aminophenol as the spacer unit were prepared. First, the nona-peptide 1 was synthesized manually by a stepwise liquid-phase procedure. The synthesis of 2a-c is shown in Chart 2. Aminophenoxyacetates 3a-c as spacers were prepared from the corresponding nitrophenols and tertbutyl bromoacetate. 19, 20) Coupling of compounds 3a-c with 9-fluorenylmethoxycarbonyl (Fmoc)-Tyr(Bn) in the presence of 1-benzotriazoyloxy-tris-dimethylaminophosphonium hexafluorophosphate (BOP) and 1-hydroxy-1H-benzotriazole (HOBt) in N,N-dimethylformamide (DMF) gave compounds 4a-c in 72%, 73% and 86% yield, respectively. The deprotection of tert-butyl group of 4a-c with trifluoroacetic acid (TFA) afforded compounds 5a, 5b, and 5c in 71%, quant. and 93% yield, respectively. Compounds 5a-c were coupled with penta-peptide 6 in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl) and HOBt in DMF to give compounds 7a-c in 78%, 81% and 95% yield, respectively. Finally, hydrogenolysis of compounds 7a-c catalyzed by 20% Pd(OH) 2 in EtOH-AcOH (6 : 1) at 45°C, followed by treatment with TFA-CH 2 Cl 2 -anisole-ethanedithiol (43 : 50 : 2 : 5), then 20% piper-idine-DMF afforded target compounds 2a-c in 75%, 67% and 67% yields, respectively.
Biological Activity
The anti-HIV-1 activities of 1 and 2a-c are shown in Table 1 . The anti-HIV-1 activity was tested by the syncytiumformation assay method using MT-4 cells according to our previously reported method. 8) Among the synthesized compounds, interestingly, 2b as m-aminophenoxyacetic acid type showed the most potent inhibitory activity against HIV-1 and had cytotoxicity at 1000 mg/ml. This finding is in distinct contrast to the result that peptide 1 derived from the native sequence of CCR5 had little antiviral activity against HIV-1. However, 2a had a moderate activity and 2c was practically inactive against HIV-1. The reason compound 2b showed higher inhibitory activity is unclear in this study, but there is the possibility that the configuration of aminophenoxyacetic acid derivatives as a non-peptide spacer affects the expression of antiviral activity against HIV-1.
In conclusion, it was demonstrated that the Ala-Ala-Ala sequence of the peptide moiety could be replaced with a nonpeptide spacer. Synthesized peptide analogues are attractive candidates as new lead compounds for the development of chemokine receptor-directed anti-HIV-1 drugs.
Experimental
All melting points are uncorrected. Optical rotations were measured with a JASCO P-1030 polarimeter. IR spectra were recorded on a JASCO IR-810 spectrometer.
1 H-NMR spectra were recorded with a JEOL JNM-EX 270 (270 MHz) spectrometer.
1 H chemical shifts are given in ppm relative to Me 4 Si (dϭ0) in CDCl 3 or CD 3 OD as internal standards at ambient temperature. Fast atom bombardment (FAB) mass spectra were obtained with a JEOL JMS SX-102 mass spectrometer in the positive ion mode using NBA or glycerol-thioglycerol matrix. Column chromatography was performed on silica gel 60 (70-230 mesh, Merck) and Sephadex LH-20 (Pharmacia). Precoated thin-layer chromatography (TLC) plates (silica gel 60-F 254 (Merck)) were used to monitor the reaction and ascertain the purity of the reaction products. The spots were detected by spraying the plates with 5% Compd.
Drug concentration (mg/ml) b)
Cytotoxicity 1000 100 10 (1000 mg/ml)
(dual cell-tropic HIV strain) syncytium assay; b) inhibitory activity: Ϫ, 0%; ϩ, Ͻ10%; ϩϩ, 10-50%; c) not determined. 
tert-Butyl
[2-(N a a -9-Fluorenylmethoxycarbonyl-O-benzyl-L-tyrosinamido)phenoxy]acetate (4a) BOP (2.44 g, 4.7 mmol) was added to a solution of 3a (0.88 g, 3.9 mmol), Fmoc-L-Tyr(Bn) (1.93 g, 3.9 mmol) and HOBt (0.63 g, 4.7 mmol) in DMF (15 ml) at 0°C and the mixture was stirred for 1 h at 0°C and 15 h at room temperature under an Ar atmosphere. After removal of the solvent, the residue was dissolved in CH 2 Cl 2 and washed with saturated aqueous NaHCO 3 , 10% aqueous citric acid and saturated aqueous NaCl, dried over anhydrous MgSO 4 
5c (p-Form Compound)
The reaction was carried out using 4c (1.39 g, 2.0 mmol) in a manner similar to the preparation of 5a to give 5c (1.20 
